Complete response letter for AstraZeneca and Abbott's Certriad
This article was originally published in Scrip
Executive Summary
TheUS FDA has issued a complete response letter to AstraZeneca and Abbott for their NDA for Certriad (rosuvastatin/fenofibric acid delayed release) capsules.